Shopping Cart
- Remove All
- Your shopping cart is currently empty
PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $46 | In Stock | |
5 mg | $109 | In Stock | |
10 mg | $178 | In Stock | |
25 mg | $397 | In Stock | |
50 mg | $678 | In Stock | |
100 mg | $995 | In Stock | |
500 mg | $2,160 | In Stock | |
1 mL x 10 mM (in DMSO) | $107 | In Stock |
Description | PHA 543613 is a specific agonist of α7 nAChR (Ki = 8.8 nM) and can be used in studies about the cognitive deficits of Alzheimer's disease and schizophrenia. |
Targets&IC50 | α7 nAChR:8.8 nM (Ki) |
In vivo | In rats, PHA-543613 (0.3 mg/kg) reverses Scopolamine-induced short-term memory deficits[2]. Intraperitoneal injection of PHA-543613 (4 and 12 mg/kg) increases p-Akt and decreases p-GSK-3 and CC3 expressions in the ipsilateral hemisphere. PHA-543613 reduces neuronal cell death in the perihematomal area[3]. |
Molecular Weight | 271.31 |
Formula | C15H17N3O2 |
Cas No. | 478149-53-0 |
Smiles | O=C(N[C@H]1CN2CCC1CC2)c1cc2ccoc2cn1 |
Relative Density. | 1.32 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 225.0 mg/mL (829.3 mM), Sonication is recommended. H2O: < 30.78 mg/mL | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.